WO2022181609A1 - 変形性関節症を治療するための貼付剤 - Google Patents
変形性関節症を治療するための貼付剤 Download PDFInfo
- Publication number
- WO2022181609A1 WO2022181609A1 PCT/JP2022/007229 JP2022007229W WO2022181609A1 WO 2022181609 A1 WO2022181609 A1 WO 2022181609A1 JP 2022007229 W JP2022007229 W JP 2022007229W WO 2022181609 A1 WO2022181609 A1 WO 2022181609A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- diclofenac
- administration
- patch according
- time
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 33
- 229960001193 diclofenac sodium Drugs 0.000 claims abstract description 54
- 239000010410 layer Substances 0.000 claims abstract description 54
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims abstract description 54
- 239000012790 adhesive layer Substances 0.000 claims abstract description 43
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000853 adhesive Substances 0.000 claims abstract description 28
- 230000001070 adhesive effect Effects 0.000 claims abstract description 28
- 150000007524 organic acids Chemical class 0.000 claims abstract description 21
- 229960001259 diclofenac Drugs 0.000 claims description 57
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 57
- 230000036470 plasma concentration Effects 0.000 claims description 37
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
- -1 glycerin ester Chemical class 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 14
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 14
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 14
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 10
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 10
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 10
- 239000005642 Oleic acid Substances 0.000 claims description 10
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 10
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 10
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 229920002367 Polyisobutene Polymers 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 claims description 9
- 239000013032 Hydrocarbon resin Substances 0.000 claims description 8
- 125000002723 alicyclic group Chemical group 0.000 claims description 8
- 229920006270 hydrocarbon resin Polymers 0.000 claims description 8
- 210000003127 knee Anatomy 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 8
- 208000003947 Knee Osteoarthritis Diseases 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- 230000003203 everyday effect Effects 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 238000000034 method Methods 0.000 description 32
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 19
- 229920001971 elastomer Polymers 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000005060 rubber Substances 0.000 description 13
- 235000015165 citric acid Nutrition 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000035699 permeability Effects 0.000 description 9
- 229920005989 resin Polymers 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229920000139 polyethylene terephthalate Polymers 0.000 description 6
- 239000005020 polyethylene terephthalate Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 239000004745 nonwoven fabric Substances 0.000 description 4
- 229920000728 polyester Polymers 0.000 description 4
- 239000004814 polyurethane Substances 0.000 description 4
- 231100000245 skin permeability Toxicity 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000003522 acrylic cement Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 229940100463 hexyl laurate Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 3
- 229920001083 polybutene Polymers 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000010734 process oil Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 150000003505 terpenes Chemical class 0.000 description 3
- 235000007586 terpenes Nutrition 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000005062 Polybutadiene Substances 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229920006271 aliphatic hydrocarbon resin Polymers 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920005549 butyl rubber Polymers 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 229940031569 diisopropyl sebacate Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XFKBBSZEQRFVSL-UHFFFAOYSA-N dipropan-2-yl decanedioate Chemical compound CC(C)OC(=O)CCCCCCCCC(=O)OC(C)C XFKBBSZEQRFVSL-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 229920003049 isoprene rubber Polymers 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 2
- 229920002857 polybutadiene Polymers 0.000 description 2
- 239000011112 polyethylene naphthalate Substances 0.000 description 2
- 229920001195 polyisoprene Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000013464 silicone adhesive Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229920003048 styrene butadiene rubber Polymers 0.000 description 2
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- CEGRHPCDLKAHJD-UHFFFAOYSA-N 1,1,1-propanetricarboxylic acid Chemical compound CCC(C(O)=O)(C(O)=O)C(O)=O CEGRHPCDLKAHJD-UHFFFAOYSA-N 0.000 description 1
- YHMYGUUIMTVXNW-UHFFFAOYSA-N 1,3-dihydrobenzimidazole-2-thione Chemical compound C1=CC=C2NC(S)=NC2=C1 YHMYGUUIMTVXNW-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- ROGIWVXWXZRRMZ-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1 ROGIWVXWXZRRMZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 239000010495 camellia oil Substances 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- NDORGWUNFGHGKU-UHFFFAOYSA-N dodecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCC(O)=O NDORGWUNFGHGKU-UHFFFAOYSA-N 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960002389 glycol salicylate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940105112 magnesium myristate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- DMRBHZWQMKSQGR-UHFFFAOYSA-L magnesium;tetradecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O DMRBHZWQMKSQGR-UHFFFAOYSA-L 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001921 poly-methyl-phenyl-siloxane Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920006306 polyurethane fiber Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 229960004029 silicic acid Drugs 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- MSFGZHUJTJBYFA-UHFFFAOYSA-M sodium dichloroisocyanurate Chemical compound [Na+].ClN1C(=O)[N-]C(=O)N(Cl)C1=O MSFGZHUJTJBYFA-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003784 tall oil Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229940098697 zinc laurate Drugs 0.000 description 1
- 229940105125 zinc myristate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229940012185 zinc palmitate Drugs 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- 229940118257 zinc undecylenate Drugs 0.000 description 1
- GPYYEEJOMCKTPR-UHFFFAOYSA-L zinc;dodecanoate Chemical compound [Zn+2].CCCCCCCCCCCC([O-])=O.CCCCCCCCCCCC([O-])=O GPYYEEJOMCKTPR-UHFFFAOYSA-L 0.000 description 1
- GJAPSKMAVXDBIU-UHFFFAOYSA-L zinc;hexadecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O GJAPSKMAVXDBIU-UHFFFAOYSA-L 0.000 description 1
- GBFLQPIIIRJQLU-UHFFFAOYSA-L zinc;tetradecanoate Chemical compound [Zn+2].CCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCC([O-])=O GBFLQPIIIRJQLU-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
Definitions
- the present invention relates to a patch for treating osteoarthritis.
- Patent Document 1 A method of administering a transdermal preparation containing diclofenac has been proposed as a method for treating osteoarthritis.
- Patent Document 2 As external preparations containing diclofenac sodium, for example, patches containing diclofenac sodium, dimethylsulfoxide and citric acid (Patent Document 2) are known.
- the inventors of the present invention conducted a detailed study of the composition and administration method of a patch containing diclofenac sodium at a high concentration for the treatment of osteoarthritis. As a result, they found an effective and safe patch and completed the present invention. came to.
- a patch for treating osteoarthritis of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, the adhesive layer comprising an adhesive base, diclofenac sodium and dimethylsulfoxide. and an organic acid, and the content of the organic acid is 6% by mass to 8% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
- the patch is applied to the affected area once a day, and the dose of diclofenac sodium per application is 70 mg to 150 mg.
- the present invention can provide an effective and safe patch for treating osteoarthritis.
- the patch for treating osteoarthritis of the present invention comprises a support layer and an adhesive layer laminated on the support layer.
- the pressure-sensitive adhesive layer is usually laminated on one side of the support layer, and if necessary, a peelable film is laminated on the other side of the pressure-sensitive adhesive layer.
- the adhesive layer is the part that is pressed against the skin when the patch is applied, and contains an adhesive base, diclofenac sodium, dimethylsulfoxide and an organic acid.
- Diclofenac sodium is a non-steroidal anti-inflammatory drug and an active ingredient in the treatment of osteoarthritis.
- the content of diclofenac sodium is preferably 1% by mass to 10% by mass or 3% by mass to 7% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
- the adhesive base may contain at least one adhesive base selected from a rubber adhesive base, an acrylic adhesive base and a silicone adhesive base.
- rubber adhesive bases include styrene-butadiene block copolymers, styrene-butadiene-styrene block copolymers, styrene-isoprene block copolymers, styrene-isoprene-styrene block copolymers, polyisobutylene, natural rubber, Alkyl vinyl ether (co)polymers, polyisoprene, polybutadiene, etc. may be mentioned, and one of these may be used alone, or two or more thereof may be used in combination.
- styrene-isoprene-styrene block copolymer polyisobutylene, or a combination thereof is preferable from the viewpoint of increasing the skin permeability of diclofenac sodium and further increasing the adhesiveness of the patch.
- a mixture of styrene block copolymer and polyisobutylene is more preferred.
- styrene-isoprene-styrene block copolymer examples include Quintac (registered trademark) 3570C (trade name, manufactured by Zeon Corporation), SIS5002, SIS5229, SIS5505 (trade name, manufactured by JSR Corporation), SIBSTAR (registered Trademark) T102 (trade name, manufactured by Kaneka Corporation), etc.
- Polyisobutylene also includes so-called butyl rubber (isobutylene-isoprene rubber), and specific examples include Oppanol (registered trademark) N50, N80, N100, N150, B11, B12, B50, B80, B100, B120, B150, B220 (trade name, manufactured by BASF), JSR (registered trademark) Butyl065, 268, 365 (trade name, manufactured by JSR Corporation), X_Butyl ( Registered trademark) RB100, 101-3, 301, 402 (trade name, manufactured by ARLANXEO), Exxon (registered trademark) Butyl065, 065S, 068, 068S, 268, 268S, 365, 365S (trade name, manufactured by Exxon Mobile) etc.
- butyl rubber isobutylene-isoprene rubber
- specific examples include Oppanol (registered trademark) N50, N80, N100, N150, B11, B12, B50, B80,
- Acrylic adhesive bases include, for example, (meth) acrylic acid, 2-ethylhexyl (meth) acrylate, methyl (meth) acrylate, butyl (meth) acrylate, hydroxyethyl (meth) acrylate, and the like (meth )
- a pressure-sensitive adhesive obtained by polymerizing or copolymerizing at least one of acrylic monomers.
- the silicone-based adhesive base contains, for example, silicone rubber such as polydimethylsiloxane, polymethylvinylsiloxane, and polymethylphenylsiloxane as a main component.
- the content of the adhesive base is 10% to 70% by weight, 20% to 50% by weight, based on the total weight of the adhesive layer, in terms of the adhesiveness of the patch. , 23% to 40% by weight, or 25% to 30% by weight.
- the mass ratio of the two is 4:1 to 1:4, 3:1 to 1:1, or 3:1 to A ratio of 2:1 is preferred.
- the content of the adhesive base is preferably 50% by mass to 90% by mass with respect to the total mass of the adhesive layer.
- DMSO Dimethyl sulfoxide
- the content of DMSO is 1% to 20% by weight, 2% to 10% by weight, 3% to 10% by weight, or 5% to 9% by weight with respect to the total weight of the adhesive layer. and preferred.
- the ratio of diclofenac sodium to DMSO is 1:0.3 to 1:4, 1:0.4 to 1:1:0.3 to 1:4, 1:0.4 to 1:1, from the viewpoints of improving skin permeability of diclofenac sodium and preventing precipitation of crystals of diclofenac sodium. 3, 1:0.6 to 1:3, or 1:0.72 to 1:3.
- Organic acids promotes percutaneous absorption of diclofenac sodium and/or prevents crystals of diclofenac sodium from precipitating over time.
- Organic acids include aliphatic monocarboxylic acids (formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, nonanoic acid, capric acid, lauric acid, oleic acid, linoleic acid, linolenic acid, isostearic acid, sorbic acid, pyruvic acid, etc.), aliphatic dicarboxylic acids (oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, sebacic acid, maleic acid, fumaric acid, oxaloacetic acid, etc.), and fats aliphatic carboxylic acids such as group tricarboxylic acids (aconitic acid, propanetricarboxylic
- organic acids may be used individually by 1 type, and may be used in combination of 2 or more type.
- organic acids oleic acid, citric acid, mesylic acid, or a combination thereof is preferable from the viewpoint of promoting percutaneous absorption of diclofenac sodium and preventing diclofenac sodium crystals from precipitating over time.
- a combination of acid and citric acid is more preferred.
- the content of the organic acid is 6% to 8% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
- the organic acid is a combination of oleic acid and citric acid
- the content of oleic acid is 4% to 6% by mass with respect to the total weight of the adhesive layer
- the content of citric acid is It is preferably 2% by mass to 4% by mass with respect to the total mass of.
- the adhesive layer may further contain other additives such as tackifiers, plasticizers, solubilizers, stabilizers and fillers.
- Tackifiers include, for example, rosin, rosin glycerol ester, hydrogenated rosin (also referred to as hydrogenated rosin), hydrogenated rosin glycerol ester and rosin derivatives such as pentaerythritol ester of rosin, Alcon P100 and Alcon P115 (above , trade name, manufactured by Arakawa Chemical Industries, Ltd.), aliphatic hydrocarbon resins such as Quinton B170 (trade name, manufactured by Nippon Zeon Co., Ltd.), YS Resin PX1150N and Clearon P-125 ( terpene resins such as the above (trade names, manufactured by Yasuhara Chemical Co., Ltd.), maleic acid resins, and the like.
- rosin rosin glycerol ester
- hydrogenated rosin also referred to as hydrogenated rosin
- hydrogenated rosin glycerol ester hydrogenated rosin glycerol ester and rosin derivative
- hydrogenated rosin glycerin esters alicyclic saturated hydrocarbon resins, aliphatic hydrocarbon resins and terpene resins are preferred, and alicyclic saturated hydrocarbon resins are more preferred.
- alicyclic saturated hydrocarbon resins are more preferred.
- Two or more of these tackifying resins may be combined.
- the content of the tackifying resin is, for example, 5% to 60% by mass, 10% to 50% by mass, 30% to 45% by mass, or 35% to 40% by mass, based on the total mass of the adhesive layer. % by mass is preferred.
- a combination of an alicyclic saturated hydrocarbon resin and a hydrogenated rosin glycerin ester is more preferable.
- the weight ratio of the alicyclic saturated hydrocarbon resin to the hydrogenated rosin glycerin ester is preferably 4:1 to 1:4, 4:1 to 2:3, or 3:1 to 2:1.
- Plasticizers include, for example, petroleum oils such as paraffinic process oils, naphthenic process oils and aromatic process oils; squalane; squalene; vegetable oils such as olive oil, camellia oil, castor oil, tall oil and peanut oil; silicone oil; dibasic acid esters such as dibutyl phthalate and dioctyl phthalate; liquid rubbers such as polybutene and liquid isoprene rubber; liquid fatty acid esters such as isopropyl myristate, hexyl laurate, diethyl sebacate and diisopropyl sebacate; glycol; glycol salicylate; propylene glycol; dipropylene glycol; triacetin; triethyl citrate; Among these, liquid paraffin, liquid polybutene, isopropyl myristate, diethyl sebacate and hexyl laurate are preferred, liquid polybutene, isopropyl myristate and liquid paraffin are more preferred
- the content of the plasticizer is, for example, 7% to 70% by mass, 8% to 40% by mass, 10% to 20% by mass, or 12% to 15% by mass with respect to the total mass of the adhesive layer. %.
- Dissolving agents include, for example, liquid fatty acid esters (isopropyl myristate, hexyl laurate, diethyl sebacate, diisopropyl sebacate, etc.), diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, triacetin, triethyl citrate. , crotamiton and the like.
- diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol and dipropylene glycol are preferred, and polyethylene glycol is more preferred.
- the dissolving agent is polyethylene glycol
- the polyethylene glycol may have a number average molecular weight of 200 to 20,000, preferably 400 to 6,000, and more preferably 1,000 to 6,000. Two or more of these dissolving agents may be combined.
- the content of the dissolving agent is preferably 0.1% by mass to 10% by mass or 0.5% by mass to 5% by mass based on the total mass of the adhesive layer.
- Stabilizers include fatty acid metal salts (zinc undecylenate, zinc stearate, magnesium stearate, calcium stearate, aluminum stearate, sodium stearate, zinc palmitate, zinc myristate, magnesium myristate, zinc laurate, lauric acid sodium, etc.), antioxidants (tocopherol derivatives, ascorbic acid derivatives, erythorbic acid derivatives, nordihydroguaiaretic acid, gallic acid derivatives, dibutylhydroxytoluene (BHT), butylhydroxyanisole, 2-mercaptobenzimidazole, etc.), ultraviolet rays absorbents (imidazole derivatives, benzotriazole derivatives, p-aminobenzoic acid derivatives, anthranilic acid derivatives, salicylic acid derivatives, cinnamic acid derivatives, benzophenone derivatives, coumaric acid derivatives, camphor derivatives, etc.).
- fatty acid metal salts zinc undec
- Two or more of these stabilizers may be used in combination.
- aliphatic metal salts are preferred, at least one component selected from the group consisting of zinc stearate and magnesium stearate is more preferred, and a combination of zinc stearate and magnesium stearate is particularly preferred.
- the content of the stabilizer is preferably 0% by mass to 5% by mass or 0% by mass to 2% by mass based on the total mass of the pressure-sensitive adhesive layer.
- the stability of diclofenac sodium can be improved by containing a stabilizer in the adhesive layer.
- Fillers include metal oxides (zinc oxide, titanium oxide, etc.), metal salts (calcium carbonate, magnesium carbonate, zinc stearate, etc.), silicate compounds (kaolin, talc, bentonite, aerosil, hydrated silica, aluminum silicate, magnesium silicate, magnesium aluminometasilicate, etc.), metal hydroxides (aluminum hydroxide, etc.), and the like. Two or more of these fillers may be combined.
- the content of the filler is preferably 0% to 10% by weight or 0% to 5% by weight based on the total weight of the pressure-sensitive adhesive layer.
- the pressure-sensitive adhesive layer may be a single layer composed of one composition, or may be a multilayer composed of a plurality of layers having different compositions.
- the mass of the adhesive layer as a whole is 10 g/m 2 to 1000 g/m 2 , 30 g/m 2 to 300 g/m 2 , 150 g/m 2 to 250 g/m 2 from the viewpoint of proper adhesion of the patch to the skin. m 2 or preferably between 190 g/m 2 and 240 g/m 2 .
- the total thickness of the adhesive layer is preferably 10 ⁇ m to 1000 ⁇ m, 30 ⁇ m to 300 ⁇ m, 150 ⁇ m to 250 ⁇ m, or 190 ⁇ m to 240 ⁇ m when the specific gravity of the adhesive layer is 1.
- the support layer holds the adhesive layer.
- the support layer is preferably a single layer or laminate of fabric (woven fabric, non-woven fabric, or knitted fabric) or non-porous or porous film (sheet).
- Materials for the support layer include polyester (polyethylene terephthalate (PET), polyethylene isophthalate, polypropylene terephthalate, polypropylene isophthalate, polybutylene terephthalate, polyethylene naphthalate, etc.), polyolefin (ethylene, propylene, vinyl acetate, acrylonitrile, etc.).
- the fabric (woven, nonwoven, or knitted) may be coated with a rubber composition.
- the rubber composition contains a rubber-based adhesive.
- Rubber-based adhesives include, for example, polyisoprene, polyisobutylene, polybutadiene, styrene-butadiene-styrene block copolymer, styrene-isoprene-styrene block copolymer, styrene-butadiene rubber, styrene-isoprene rubber, or combinations thereof.
- the rubber composition may contain a tackifier. Tackifiers are, for example, alicyclic saturated hydrocarbon resins, hydrogenated rosin esters, terpene resins, or combinations thereof.
- the rubber composition may further contain additives such as plasticizers and fillers.
- the thickness of the support layer is, for example, 0.1 mm to 2 mm.
- the basis weight of the support layer is, for example, 30 g/m 2 to 200 g/m 2 . In this specification, the thickness and basis weight of the support layer are measured according to the JIS L 1913:2010 standard.
- the moisture permeability of the support layer is preferably 1000 g/m 2 ⁇ 24 hours or more.
- DMSO is gradually volatilized from the patch applied to the skin, so that the adhesiveness of the patch is improved, and even if the patch is applied for a long time, the patch will come off. Hateful.
- the upper limit of moisture permeability may be 20000 g/m 2 ⁇ 24 hours.
- DMSO is more likely to volatilize from the adhesive layer, which is more effective in improving the adhesiveness of the patch.
- the moisture permeability of the support layer means the moisture permeability at 40° C. defined in the JIS Z0208:1976 standard (moisture-proof packaging material moisture permeability test method (cup method)).
- the 50% modulus (JIS L 1018: 1999) in both the longitudinal direction (material flow direction) and the lateral direction (material width direction) of the support layer is 1 N/50 mm or more. It is preferably 12N/50mm.
- the 50% modulus is 12 N/50 mm or less, the patch receives less stress due to skin expansion and contraction, and thus has good adhesion to the skin.
- the material preferably has high moisture permeability (high DMSO permeability) such as polyurethane.
- high DMSO permeability such as polyurethane.
- a film made of polyurethane has excellent stretchability, and is therefore preferable from the viewpoint of improving the adhesiveness of the patch to the skin and the stretchability of the patch.
- the support layer is preferably, for example, a nonwoven fabric or film made of polyurethane, a knitted fabric made of polyethylene terephthalate, a polyester fabric coated with a rubber composition, or a combination thereof. More specifically, the support layer is preferably a laminate of a polyurethane film and a nonwoven fabric made of polyurethane fibers, a nonwoven fabric made of PET fibers, or a polyester fabric coated with a rubber composition.
- the peelable film covers the pressure-sensitive adhesive layer before use of the patch, and can be peeled off and removed at the time of use.
- Specific examples include polyethylene terephthalate, polyethylene naphthalate, and the like.
- polyolefins such as polyester, polyethylene and polypropylene; films such as polyvinyl chloride and polyvinylidene chloride; laminated films of woodfree paper and polyolefin; and films such as nylon and aluminum.
- these peelable films are preferably surface-coated (release-treated) with a release agent such as silicone or polytetrafluoroethylene.
- the application area of the patch should be 30 cm 2 to 300 cm 2 , 50 cm 2 to 150 cm 2 , or 70 cm 2 to 140 cm 2 . preferable.
- a patch can be manufactured, for example, by the following method, but is not limited to this, and a known method can be used.
- each component constituting the pressure-sensitive adhesive layer is mixed in a predetermined ratio to obtain a uniform melt.
- the dissolved material is spread to a predetermined thickness on a peelable film or support layer to form an adhesive layer.
- the backing layer is pressed against the adhesive layer or the peelable film so that the adhesive layer is sandwiched between the peelable film and the backing layer.
- a patch can be obtained by cutting into a desired shape. In this case the peelable film is removed during application of the patch.
- the support layer may be pressure-bonded to the peelable film.
- the patch is applied to the affected area (knee, groin, elbow, shoulder, etc.) of an adult human once a day, and is replaced every day (about 24 hours).
- the dose of diclofenac sodium per dose is 70 mg to 150 mg.
- Dose means diclofenac sodium contained in the patch to be applied.
- the dose may be the content of diclofenac sodium contained in one patch, or the total content of diclofenac sodium contained in a plurality of patches.
- the dose is 70 mg to 150 mg.
- the dose is 75 mg or 150 mg.
- the dosage is 100 mg or 150 mg.
- the above patches are effective in treating osteoarthritis. More specifically, it is effective in relieving pain in osteoarthritis.
- the patch is particularly effective for knee osteoarthritis among osteoarthritis.
- it is preferable to apply the patch to the inner and outer sides of the knee alternately every day. Such administration can avoid skin irritation, increase the local concentration of diclofenac sodium in the knee joint, and enhance the therapeutic efficacy of knee osteoarthritis.
- a single dose administration of 150 mg of diclofenac sodium to an adult human has a maximum plasma concentration (C max ) of diclofenac of 19 ng/mL to 23 ng/mL, reaching the maximum plasma concentration (C max ). It is preferable that the time (t max ) is 6 to 18 hours, and the area under the plasma drug concentration-time curve (AUC 0-t ) of diclofenac from the time of administration to the final time point of concentration measurement is 300 ng ⁇ h.
- the area under the plasma drug concentration-time curve (AUC 0-inf ) of diclofenac when extrapolated from the time of administration to infinity time is 300 ng ⁇ h/mL to It is preferably 400 ng ⁇ h/mL
- the plasma concentration half-life (t 1/2 ) of diclofenac is preferably 6 to 8 hours
- the apparent dose of diclofenac is 13 to 16 mg.
- the diclofenac release rate (% Drug released) is 8.6% to 10.7%.
- a patch exhibiting such pharmacokinetic parameters is excellent in safety and efficacy in the treatment of osteoarthritis.
- the maximum diclofenac plasma concentration (C ss max ) is 30 ng/mL to 65 ng/mL, and the above The time to reach maximum plasma concentration (C ss max ) (t ss max ) is preferably between 3 and 6 hours, and the area under the diclofenac plasma drug concentration-time curve (AUC ss 0 ⁇ t ) is preferably 400 ng ⁇ h/mL to 700 ng ⁇ h/mL, the plasma concentration half-life (t ss 1/2 ) of diclofenac is preferably 1 hour to 5 hours, and A patch having an apparent dose of 14 mg to 21 mg and a diclofenac release rate (% drug released) of 9.3% to 14% is preferred. A patch exhibiting such pharmacokinetic parameters is excellent in safety and efficacy in the treatment of osteoarthritis.
- a single dose administration of 107 mg of diclofenac sodium to an adult human has a maximum plasma concentration (C max ) of 10 ng/mL to 13 ng/mL of diclofenac, reaching the maximum plasma concentration (C max ). is preferably 10 to 15 hours, and the area under the plasma drug concentration-time curve (AUC 0-t ) of diclofenac from the time of administration to the final time point of concentration measurement was 140 ng ⁇ h.
- AUC 0-inf area under the plasma drug concentration-time curve
- t 1/2 half-life of diclofenac plasma concentration
- a method for treating osteoarthritis comprising the step of administering a patch to a patient, wherein the patch comprises a backing layer and an adhesive layer laminated on the backing layer,
- the pressure-sensitive adhesive layer contains an adhesive base, diclofenac sodium, dimethylsulfoxide and an organic acid, and the content of the organic acid is 6% to 8% by weight with respect to the total weight of the pressure-sensitive adhesive layer.
- the method, wherein the patch is applied to the affected area once a day, and the dose of diclofenac sodium per application is 70 mg to 150 mg.
- the method according to [1], wherein the patch has an area of 70 cm 2 to 140 cm 2 .
- the patch has an area under the plasma drug concentration-time curve of diclofenac from the time of single administration to the final concentration measurement point of 300 ng ⁇ h/mL to 400 ng ⁇ h/mL.
- the patch has an area under the plasma drug concentration-time curve of 300 ng ⁇ h/mL to 400 ng ⁇ h/mL when extrapolated from the time of single administration to infinite time.
- the method of [1] which is a patch.
- the method of [1] wherein the patch has a plasma concentration half-life of 6 to 8 hours after single administration.
- the plasma drug concentration of diclofenac in the dosing interval when the patch reaches a steady state after repeated administration once a day - the area under the time curve is 400 ng ⁇ h/mL to 700 ng ⁇ h/mL;
- the method of [1], which is a patch is a patch.
- Method. A patch in which the diclofenac release amount is 14 mg to 21 mg and the diclofenac release rate is 9.3% to 14% when the above patch reaches a steady state after repeated administration once a day.
- the patch has a maximum diclofenac plasma concentration of 10 ng/mL to 13 ng/mL upon single administration, and the time required to reach the maximum plasma concentration is 10 to 15 hours.
- the above-mentioned patch has an area under the diclofenac plasma drug concentration-time curve of 140 ng ⁇ h/mL to 200 ng ⁇ h/mL from the time of administration to the final time point of concentration measurement at the time of single administration. The method according to [1].
- the above-mentioned patch has an area under the plasma drug concentration-time curve of 150 ng ⁇ h/mL to 200 ng ⁇ h/mL of diclofenac when extrapolated from the time of administration to an infinite time during single administration.
- the adhesive patch contains a styrene-isoprene-styrene block copolymer and polyisobutylene as the adhesive base.
- a patch used in a method for treating osteoarthritis comprising a backing layer and an adhesive layer laminated on the backing layer, wherein the adhesive layer contains an adhesive base, diclofenac sodium, dimethylsulfoxide and an organic acid, the content of the organic acid is 6% by mass to 8% by mass with respect to the total mass of the adhesive layer, and the patch is 1
- a patch that is applied to an affected area once a day, and the dosage of diclofenac sodium per application is 70 mg to 150 mg.
- the patch of [21] wherein the patch has an area of 70 cm 2 to 140 cm 2 .
- the area under the plasma drug concentration-time curve of diclofenac from the time of administration to the final time point of concentration measurement is 300 ng ⁇ h/mL to 400 ng ⁇ h/mL upon single administration of the patch, [21 ] to [26].
- the area under the plasma drug concentration-time curve of diclofenac is 300 ng ⁇ h/mL to 400 ng ⁇ h/mL when extrapolated from the time of administration to an infinite time during single administration of the patch. , the patch according to any one of [21] to [27].
- the area under the plasma drug concentration-time curve is 400 ng ⁇ h/mL to 700 ng ⁇ h/mL at intervals of diclofenac dosing when a steady state is reached by repeated once-daily administration of the patch.
- the patch according to any one of [21] to [31].
- the release amount of diclofenac is 14 mg to 21 mg and the release rate of diclofenac is 9.3% to 14% when a steady state is reached by repeated once-daily administration of the patch, [21 ] to [33].
- the maximum plasma concentration of diclofenac upon single administration of the patch is 10 ng/mL to 13 ng/mL, and the time required to reach the maximum plasma concentration is 10 to 15 hours. 21] The patch according to any one of [25].
- the area under the plasma drug concentration-time curve of diclofenac from the time of administration to the final time point of concentration measurement is 140 ng ⁇ h/mL to 200 ng ⁇ h/mL upon single administration of the patch, [21 ] to [25], the patch according to any one of [34a].
- the area under the plasma drug concentration-time curve of diclofenac is 150 ng ⁇ h/mL to 200 ng ⁇ h/mL when extrapolated from the time of administration to an infinite time during single administration of the patch. , [21] to [25], [34a] to [34b].
- the adhesive layer contains an alicyclic saturated hydrocarbon resin and a hydrogenated rosin glycerin ester.
- a patch containing diclofenac sodium was prepared by the following method.
- Each component of the pressure-sensitive adhesive layer (components shown in Table 1) was uniformly mixed and spread on a release liner (a PET liner subjected to release treatment) so that the mass of the paste was 214 g/m 2 .
- a support layer was laminated on the spread pressure-sensitive adhesive layer and cut into a size of 100 cm 2 to obtain a patch (the content of diclofenac sodium per unit area was 10.7 g/m 2 , and one sheet containing 107 mg diclofenac sodium per patch).
- WOMAC Osteoarthritis Index
- Results The results of single administration are shown in Table 4, and the results of multiple administration are shown in Table 5, respectively.
- the numbers in the table represent mean values (% coefficient of variation), while t max and t ss max represent medians (minimum-maximum).
- Example 3 Application of Patch to Subjects The patch of Example 3 was applied to 20 healthy subjects on the inside or outside of the knee for 24 hours to evaluate the pharmacokinetics of diclofenac sodium.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
[1] 患者に貼付剤を投与する工程を含む変形性関節症を治療するための方法であって、上記貼付剤は支持体層と支持体層上に積層された粘着剤層とを備え、上記粘着剤層が、粘着基剤、ジクロフェナクナトリウム、ジメチルスルホキシド及び有機酸を含み、上記有機酸の含有量は、上記粘着剤層の全質量に対して6質量%~8質量%であり、上記貼付剤は1日1回患部に貼付され、1回あたりのジクロフェナクナトリウムの投与量が70mg~150mgである、方法。
[2]上記貼付剤の面積が70cm2~140cm2である、[1]に記載の方法。
[3]上記貼付剤の膏体質量が190g/m2~240g/m2である、[1]に記載の方法。
[4]変形性関節症が変形性膝関節症である、[1]に記載の方法。
[5]上記貼付剤が膝の内側と外側に1日毎に交互に貼付される、[4]に記載の方法。
[6]上記貼付剤が、単回投与時のジクロフェナクの最高血漿中濃度が19ng/mL~23ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が6時間~18時間である貼付剤である、[1]に記載の方法。
[7]上記貼付剤が、単回投与時の投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである貼付剤である、[1]に記載の方法。
[8]上記貼付剤が、単回投与時の投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである貼付剤である、[1]に記載の方法。
[9]上記貼付剤が、単回投与時のジクロフェナクの血漿中濃度の半減期が6時間~8時間である貼付剤である、[1]に記載の方法。
[10]上記貼付剤が、単回投与時のジクロフェナクの放出量が13mg~16mgであり、ジクロフェナクの放出率が8.6%~10.7%である貼付剤である、[1]に記載の方法。
[11]上記貼付剤が、1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの最高血漿中濃度が30ng/mL~65ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が3時間~6時間である貼付剤である、[1]に記載の方法。
[12]上記貼付剤が、1日1回投与を繰り返して定常状態に達した場合の投与間隔におけるジクロフェナクの血漿中薬物濃度-時間曲線下面積が400ng・h/mL~700ng・h/mLである貼付剤である、[1]に記載の方法。
[13]上記貼付剤が、1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの血漿中濃度の半減期が1時間~5時間である貼付剤である、[1]に記載の方法。
[14]上記貼付剤が、1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの放出量が14mg~21mgであり、ジクロフェナクの放出率が9.3%~14%である貼付剤である、[1]に記載の方法。
[14a]上記貼付剤が、単回投与時のジクロフェナクの最高血漿中濃度が10ng/mL~13ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が10時間~15時間である貼付剤である、[1]に記載の方法。
[14b]上記貼付剤が、単回投与時の、投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が140ng・h/mL~200ng・h/mLである貼付剤である、[1]に記載の方法。
[14c]上記貼付剤が、単回投与時の、投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が150ng・h/mL~200ng・h/mLである貼付剤である、[1]に記載の方法。
[14d]上記貼付剤が、単回投与時の、ジクロフェナクの血漿中濃度の半減期が5時間~7時間である貼付剤である、[1]に記載の方法。
[15]上記貼付剤が、上記粘着基剤としてスチレン-イソプレン-スチレンブロック共重合体及びポリイソブチレンを含む貼付剤である、[1]に記載の方法。
[16]上記貼付剤が、上記粘着剤層に脂環族飽和炭化水素樹脂及び水素添加ロジングリセリンエステルを含む貼付剤である、[1]に記載の方法。
[17]上記貼付剤が、上記粘着剤層に流動パラフィンを含む貼付剤である、[1]に記載の方法。
[18]上記貼付剤が、上記粘着剤層の全質量に対して3質量%~7質量%のジクロフェナクナトリウムを含む貼付剤である、[1]に記載の方法。
[19]上記貼付剤が、上記有機酸としてオレイン酸及びクエン酸を含む貼付剤である、[1]に記載の方法。
[20]上記貼付剤が、上記粘着剤層の全質量に対して4質量%~6質量%のオレイン酸を含み、2質量%~4質量%のクエン酸を含む貼付剤である、[19]に記載の方法。
[21]変形性関節症を治療するための方法に使用される貼付剤であって、上記貼付剤は支持体層と支持体層上に積層された粘着剤層とを備え、上記粘着剤層が、粘着基剤、ジクロフェナクナトリウム、ジメチルスルホキシド及び有機酸を含み、上記有機酸の含有量は、上記粘着剤層の全質量に対して6質量%~8質量%であり、上記貼付剤は1日1回患部に貼付され、1回あたりのジクロフェナクナトリウムの投与量が70mg~150mgである、貼付剤。
[22]上記貼付剤の面積が70cm2~140cm2である、[21]に記載の貼付剤。
[23]上記貼付剤の膏体質量が190g/m2~240g/m2である、[21]又は[22]に記載の貼付剤。
[24]変形性関節症が変形性膝関節症である、[21]~[23]のいずれかに記載の貼付剤。
[25]上記貼付剤が膝の内側と外側に1日毎に交互に貼付されるように用いられる、[24]に記載の貼付剤。
[26]上記貼付剤の単回投与時のジクロフェナクの最高血漿中濃度が19ng/mL~23ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が6時間~18時間である、[21]~[25]のいずれかに記載の貼付剤。
[27]上記貼付剤の単回投与時の、投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである、[21]~[26]のいずれかに記載の貼付剤。
[28]上記貼付剤の単回投与時の、投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである、[21]~[27]のいずれかに記載の貼付剤。
[29]上記貼付剤の単回投与時の、ジクロフェナクの血漿中濃度の半減期が6時間~8時間である、[21]~[28]のいずれかに記載の貼付剤。
[30]上記貼付剤の単回投与時の、ジクロフェナクの放出量が13mg~16mgであり、ジクロフェナクの放出率が8.6%~10.7%である、[21]~[29]のいずれかに記載の貼付剤。
[31]上記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの最高血漿中濃度が30ng/mL~65ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が3時間~6時間である、[21]~[30]のいずれかに記載の貼付剤。
[32]上記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの投与間隔における血漿中薬物濃度-時間曲線下面積が400ng・h/mL~700ng・h/mLである、[21]~[31]のいずれかに記載の貼付剤。
[33]上記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの血漿中濃度の半減期が1時間~5時間である、[21]~[32]のいずれかに記載の貼付剤。
[34]上記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの放出量が14mg~21mgであり、ジクロフェナクの放出率が9.3%~14%である、[21]~[33]のいずれかに記載の貼付剤。
[34a]上記貼付剤の単回投与時のジクロフェナクの最高血漿中濃度が10ng/mL~13ng/mLであり、上記最高血漿中濃度に達するまでに要する時間が10時間~15時間である、[21]~[25]のいずれかに記載の貼付剤。
[34b]上記貼付剤の単回投与時の、投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が140ng・h/mL~200ng・h/mLである、[21]~[25]、[34a]のいずれかに記載の貼付剤。
[34c]上記貼付剤の単回投与時の、投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が150ng・h/mL~200ng・h/mLである、[21]~[25]、[34a]~[34b]のいずれかに記載の貼付剤。
[34d]上記貼付剤の単回投与時の、ジクロフェナクの血漿中濃度の半減期が5時間~7時間である、[21]~[25]、[34a]~[34c]のいずれかに記載の貼付剤。
[35]上記粘着基剤としてスチレン-イソプレン-スチレンブロック共重合体及びポリイソブチレンを含む、[21]~[34d]のいずれかに記載の貼付剤。
[36]上記粘着剤層に脂環族飽和炭化水素樹脂及び水素添加ロジングリセリンエステルを含む、[21]~[35]のいずれかに記載の貼付剤。
[37]上記粘着剤層に流動パラフィンを含む、[21]~[36]のいずれかに記載の貼付剤。
[38]上記粘着剤層の全質量に対して3質量%~7質量%のジクロフェナクナトリウムを含む、[21]~[37]のいずれかに記載の貼付剤。
[39]上記有機酸としてオレイン酸及びクエン酸を含む、[21]~[38]のいずれかに記載の貼付剤。
[40]上記粘着剤層の全質量に対して4質量%~6質量%のオレイン酸を含み、2質量%~4質量%のクエン酸を含む、[21]~[39]のいずれかに記載の貼付剤。
ジクロフェナクナトリウムを含有する貼付剤を以下の方法で調製した。粘着剤層の各成分(表1に示す成分)を均一に混和し、剥離ライナー(離型処理をしたPETライナー)上に膏体質量が214g/m2となるように展延した。展延した粘着剤層上に支持体層を積層し、100cm2の大きさに裁断し、貼付剤を得た(ジクロフェナクナトリウムの単位面積当たりの含量は10.7g/m2であり、1枚の貼付剤当たり107mgのジクロフェナクナトリウムを含む)。
ジクロフェナクナトリウムを含有しないプラセボ貼付剤を上記と同様の方法で調製した。プラセボ貼付剤の粘着剤層の成分を表2に示す。
被験者のスクリーニング
変形性膝関節症患者を対象にNumerical Rating Scale(0が痛みなし、10が想像できる最大の痛みとして、0~10までの11段階に分けて、現在の痛みがどの程度かを指し示す段階的スケール;以後「NRSスケール」という)を使用して、本試験に参加する被験者をスクリーニングした。
上記スクリーニングで適格と判定された被験者は、実施例1の貼付剤、比較例1の貼付剤又はプラセボ貼付剤、のいずれかの群に割り当てられ、その貼付剤を4週間連続して1日1回、被験者の膝の内側/外側に交互に貼付した。なお、貼付期間中の用量変更は禁止とした。
貼付開始時(ベースライン)と貼付4週目との間のWestern Ontario and McMaster Universities Osteoarthritis Index(WOMAC)LK3.10Aペインスコアの変化を測定した。WOMAC LK3.10Aペインスコアは、変形性関節症に特異的な尺度として広く使用されている。以下の5つの項目を5段階のスケール<0から4のスケール>で評価し、数値が低い方が良好な結果であることを示す<0=困難ではない、4=極めて困難である>。
1.Walking
2.Stair climbing
3.Nocturnal
4.Rest
5.Weight bearing
表3に示した結果から明らかなように、実施例1の貼付剤投与群(N=69)はプラセボ貼付剤投与群(N=143)と比較して統計的に有意な改善(痛みの緩和)をもたらした。
ジクロフェナクナトリウムを含有する貼付剤の調製
貼付剤の面積を140cm2の大きさに裁断した以外は、上記1の実施例1及び比較例1と同じ組成で実施例2および比較例2の貼付剤を得た(ジクロフェナクナトリウムの単位面積当たりの含量は10.7g/m2であり、1枚の貼付剤当たり150mgのジクロフェナクナトリウムを含む)。
18人の健康な被験者の膝に、実施例2の貼付剤及び比較例2の貼付剤又は比較例2の貼付剤及び実施例2の貼付剤をこの順に貼付し、ジクロフェナクナトリウムの単回および複数回投与の薬物動態を評価した。
単回投与の結果を表4に、複数回投与の結果を表5に、それぞれ示す。表中の数値は平均値(%変動係数)を表すが、tmax及びtss maxはメディアン(最小値-最大値)を表す。
ジクロフェナクナトリウムを含有する貼付剤の調製
上記1の実施例1と同じ組成の貼付剤(実施例3)を得た(面積100cm2、ジクロフェナクナトリウムの単位面積当たりの含量は10.7g/m2であり、1枚の貼付剤当たり107mgのジクロフェナクナトリウムを含む)。
実施例3の貼付剤を20人の健康な被験者に対して、膝の内側又は外側に24時間貼付し、ジクロフェナクナトリウムの薬物動態を評価した。
Claims (24)
- 支持体層と支持体層上に積層された粘着剤層とを備える、変形性関節症を治療するための貼付剤であって、
前記粘着剤層が、粘着基剤、ジクロフェナクナトリウム、ジメチルスルホキシド及び有機酸を含み、
前記有機酸の含有量は、前記粘着剤層の全質量に対して6質量%~8質量%であり、
前記貼付剤は1日1回患部に貼付するように用いられ、1回あたりのジクロフェナクナトリウムの投与量が70mg~150mgとなるように用いられる、
貼付剤。 - 前記貼付剤の面積が70cm2~140cm2である、請求項1に記載の貼付剤。
- 前記貼付剤の膏体質量が190g/m2~240g/m2である、請求項1又は2に記載の貼付剤。
- 変形性関節症が変形性膝関節症である、請求項1~3のいずれか一項に記載の貼付剤。
- 前記貼付剤が膝の内側と外側に1日毎に交互に貼付されるように用いられる、請求項4に記載の貼付剤。
- 前記貼付剤の単回投与時のジクロフェナクの最高血漿中濃度が19ng/mL~23ng/mLであり、前記最高血漿中濃度に達するまでに要する時間が6時間~18時間である、請求項1~5のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである、請求項1~6のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が300ng・h/mL~400ng・h/mLである、請求項1~7のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、ジクロフェナクの血漿中濃度の半減期が6時間~8時間である、請求項1~8のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、ジクロフェナクの放出量が13mg~16mgであり、ジクロフェナクの放出率が8.6%~10.7%である、請求項1~9のいずれか一項に記載の貼付剤。
- 前記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの最高血漿中濃度が30ng/mL~65ng/mLであり、前記最高血漿中濃度に達するまでに要する時間が3時間~6時間である、請求項1~10のいずれか一項に記載の貼付剤。
- 前記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの投与間隔における血漿中薬物濃度-時間曲線下面積が400ng・h/mL~700ng・h/mLである、請求項1~11のいずれか一項に記載の貼付剤。
- 前記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの血漿中濃度の半減期が1時間~5時間である、請求項1~12のいずれか一項に記載の貼付剤。
- 前記貼付剤の1日1回投与を繰り返して定常状態に達した場合のジクロフェナクの放出量が14mg~21mgであり、ジクロフェナクの放出率が9.3%~14%である、請求項1~13のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時のジクロフェナクの最高血漿中濃度が10ng/mL~13ng/mLであり、前記最高血漿中濃度に達するまでに要する時間が10時間~15時間である、請求項1~5のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、投与時から濃度測定最終時点までのジクロフェナクの血漿中薬物濃度-時間曲線下面積が140ng・h/mL~200ng・h/mLである、請求項1~5、15のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、投与時から無限大時間まで外挿したときのジクロフェナクの血漿中薬物濃度-時間曲線下面積が150ng・h/mL~200ng・h/mLである、請求項1~5、15~16のいずれか一項に記載の貼付剤。
- 前記貼付剤の単回投与時の、ジクロフェナクの血漿中濃度の半減期が5時間~7時間である、請求項1~5、15~17のいずれか一項に記載の貼付剤。
- 前記粘着基剤としてスチレン-イソプレン-スチレンブロック共重合体及びポリイソブチレンを含む、請求項1~18のいずれか一項に記載の貼付剤。
- 前記粘着剤層に脂環族飽和炭化水素樹脂及び水素添加ロジングリセリンエステルを含む、請求項1~19のいずれか一項に記載の貼付剤。
- 前記粘着剤層に流動パラフィンを含む、請求項1~20のいずれか一項に記載の貼付剤。
- 前記粘着剤層の全質量に対して3質量%~7質量%のジクロフェナクナトリウムを含む、請求項1~21のいずれか一項に記載の貼付剤。
- 前記有機酸としてオレイン酸及びクエン酸を含む、請求項1~22のいずれか一項に記載の貼付剤。
- 前記粘着剤層の全質量に対して4質量%~6質量%のオレイン酸を含み、2質量%~4質量%のクエン酸を含む、請求項1~23のいずれか一項に記載の貼付剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023502436A JPWO2022181609A1 (ja) | 2021-02-25 | 2022-02-22 | |
US18/278,304 US20240122870A1 (en) | 2021-02-25 | 2022-02-22 | Transdermal patch for treating osteoarthritis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/184,797 US11872320B2 (en) | 2021-02-25 | 2021-02-25 | Method for treating osteoarthritis |
US17/184,797 | 2021-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022181609A1 true WO2022181609A1 (ja) | 2022-09-01 |
Family
ID=82900198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/007229 WO2022181609A1 (ja) | 2021-02-25 | 2022-02-22 | 変形性関節症を治療するための貼付剤 |
Country Status (4)
Country | Link |
---|---|
US (2) | US11872320B2 (ja) |
JP (1) | JPWO2022181609A1 (ja) |
TW (1) | TW202302079A (ja) |
WO (1) | WO2022181609A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013191128A1 (ja) * | 2012-06-20 | 2013-12-27 | 久光製薬株式会社 | 貼付剤 |
WO2018124089A1 (ja) * | 2016-12-28 | 2018-07-05 | 久光製薬株式会社 | 貼付剤 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2045618B (en) | 1979-04-03 | 1983-05-11 | Hisamitsu Pharmaceutical Co | Adhesive plaster |
JPS56133381A (en) | 1980-03-25 | 1981-10-19 | Nippon Kayaku Co Ltd | Pressure-sensitive adhesive tape or sheet containing nitroglycerin |
CA1248450A (en) | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
JPS61233077A (ja) | 1985-04-09 | 1986-10-17 | Nitto Electric Ind Co Ltd | 貼付剤 |
JPS61280426A (ja) | 1985-06-04 | 1986-12-11 | Ikeda Mohandou:Kk | 消炎鎮痛用貼付剤 |
JPS62181226A (ja) | 1986-02-05 | 1987-08-08 | Ikeda Mohandou:Kk | 消炎鎮痛外用剤 |
JPS63246326A (ja) | 1987-11-07 | 1988-10-13 | Nippon Kayaku Co Ltd | ニトログリセリンを含有する感圧性粘着テープまたはシートの製造方法 |
JP3226940B2 (ja) | 1990-05-30 | 2001-11-12 | 山之内製薬株式会社 | 経皮投与製剤 |
JP2507158B2 (ja) | 1990-08-23 | 1996-06-12 | 積水化学工業株式会社 | 経皮吸収製剤 |
US5639738A (en) | 1992-02-20 | 1997-06-17 | Hyal Pharmaceutical Corporation | Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs |
JP3086290B2 (ja) | 1991-07-26 | 2000-09-11 | エスエス製薬株式会社 | ジクロフェナクナトリウム貼付剤 |
DE69228313T2 (de) | 1991-08-30 | 1999-09-23 | Hisamitsu Pharmaceutical Co | Entzündungshemmendes, analgetisches pflaster |
JP2653592B2 (ja) | 1991-12-04 | 1997-09-17 | 救急薬品工業株式会社 | 非ステロイド系薬物高放出性テープ剤 |
JPH0624969A (ja) | 1992-07-09 | 1994-02-01 | Teikoku Seiyaku Co Ltd | ケトプロフェン含有外用貼付剤 |
EP0676962B9 (en) | 1992-12-31 | 2002-04-03 | Sunkyong Industries Co., Ltd. | Enhanced pharmaceutical compositions for skin penetration for piroxicam |
JPH06219940A (ja) | 1993-01-27 | 1994-08-09 | Shiseido Co Ltd | 貼付剤 |
JP3696902B2 (ja) | 1994-07-22 | 2005-09-21 | 積水化学工業株式会社 | ニトログリセリン貼付剤の製造方法 |
DE69535737T2 (de) | 1994-09-16 | 2009-04-09 | Hisamitsu Pharmaceutical Co., Inc., Tosu-shi | Pflaster zur externen anwendung |
JP3782834B2 (ja) | 1994-10-26 | 2006-06-07 | 株式会社トクホン | 鎮痛抗炎症貼付剤 |
US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
CN1047732C (zh) | 1995-04-10 | 1999-12-29 | 浙江省医学科学院 | 石杉碱透皮吸收贴片 |
US5702720A (en) | 1995-12-22 | 1997-12-30 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of flurbiprofen |
JPH09208460A (ja) | 1996-01-31 | 1997-08-12 | Lion Corp | 貼付剤 |
JP4346696B2 (ja) | 1996-05-28 | 2009-10-21 | 久光製薬株式会社 | 経皮治療用装置 |
JPH10109945A (ja) | 1996-10-04 | 1998-04-28 | Hisamitsu Pharmaceut Co Inc | 可塑剤および該可塑剤を含有する貼付剤 |
JP4275751B2 (ja) | 1996-12-27 | 2009-06-10 | 久光製薬株式会社 | 外用組成物 |
JPH10218793A (ja) | 1997-02-03 | 1998-08-18 | Nichiban Co Ltd | 経皮吸収型消炎鎮痛用テープ剤及びその製造方法 |
JP4181232B2 (ja) | 1997-07-18 | 2008-11-12 | 帝國製薬株式会社 | ジクロフェナクナトリウム含有油性外用貼付製剤 |
JPH11255644A (ja) | 1998-03-09 | 1999-09-21 | Lintec Corp | 経皮吸収型解熱消炎鎮痛剤 |
CN1169901C (zh) | 1998-04-21 | 2004-10-06 | 科洛普拉斯特公司 | 压敏粘合剂组合物 |
JPH11322590A (ja) | 1998-05-13 | 1999-11-24 | Teijin Ltd | 新規粘着剤及び貼付製剤 |
JP4255994B2 (ja) | 1998-05-15 | 2009-04-22 | リンテック株式会社 | 経皮吸収型解熱消炎鎮痛貼付剤 |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
KR100360827B1 (ko) | 1999-08-14 | 2002-11-18 | 주식회사 삼양사 | 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법 |
JP4873768B2 (ja) | 1999-08-19 | 2012-02-08 | 久光製薬株式会社 | 経皮吸収促進剤及び経皮吸収型製剤 |
JP4659943B2 (ja) | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
DK1277466T3 (da) * | 2000-04-18 | 2011-10-17 | Hisamitsu Pharmaceutical Co | Plaster indeholdende et antiinflammatorisk middel |
JP4625157B2 (ja) | 2000-04-27 | 2011-02-02 | ニプロパッチ株式会社 | インドメタシン貼付剤 |
JP4648518B2 (ja) | 2000-06-01 | 2011-03-09 | 帝國製薬株式会社 | 4−ビフェニル酢酸含有貼付剤 |
JP2002020274A (ja) | 2000-06-12 | 2002-01-23 | San-A Seiyaku Kk | 非ステロイド性消炎鎮痛剤の外用貼付剤および外用貼付薬 |
KR20020012978A (ko) | 2000-08-10 | 2002-02-20 | 이영길 | 진통소염 효과를 갖는 디클로페낙염을 함유 카타플라스마제 |
JP4358978B2 (ja) | 2000-09-05 | 2009-11-04 | 日東電工株式会社 | 経皮吸収製剤 |
KR100406722B1 (ko) | 2000-11-06 | 2003-11-21 | 주식회사 삼양사 | 수분흡수능이 우수한 매트릭스형 경피투여제 |
JP2002193793A (ja) | 2000-12-26 | 2002-07-10 | Teikoku Seiyaku Co Ltd | 非ステロイド系消炎鎮痛貼付剤 |
JP2002226366A (ja) | 2001-02-02 | 2002-08-14 | Yuutoku Yakuhin Kogyo Kk | 外用貼付剤 |
JP4865958B2 (ja) | 2001-05-23 | 2012-02-01 | 株式会社トクホン | 鎮痛抗炎症局所作用型の貼付剤 |
DE60236084D1 (de) | 2001-05-31 | 2010-06-02 | Hisamitsu Pharmaceutical Co | Perkutan resorbierbare pflaster |
JP2003063955A (ja) | 2001-08-29 | 2003-03-05 | Nichiban Co Ltd | 経皮吸収型貼付剤 |
EP1477164B1 (en) | 2002-02-19 | 2012-06-06 | Hisamitsu Pharmaceutical Co. Inc. | Percutaneous absorption type plaster |
JP2003319967A (ja) | 2002-05-02 | 2003-11-11 | Daio Paper Corp | 貼付シートまたはテープ |
US7202322B2 (en) | 2002-11-08 | 2007-04-10 | Noveon, Inc. | Heat resistant high moisture vapor transmission thermoplastic polyurethane |
CN100372526C (zh) | 2002-11-27 | 2008-03-05 | 久光制药株式会社 | 温感敷剂 |
GB2396109B (en) | 2002-12-12 | 2006-04-19 | Johnson & Johnson Medical Ltd | Absorbent multilayer hydrogel wound dressings |
WO2004058232A1 (ja) | 2002-12-26 | 2004-07-15 | Kowa Co., Ltd. | 貼付剤 |
CN1215838C (zh) | 2003-06-25 | 2005-08-24 | 蚌埠丰原医药科技发展有限公司 | 双氯芬酸钠贴剂及其制备方法 |
CA2546200A1 (en) | 2003-11-18 | 2005-06-02 | 3M Innovative Properties Company | Olanzapine containing transdermal drug delivery compositions |
CA2576158C (en) | 2004-08-05 | 2020-10-27 | Corium International, Inc. | Adhesive composition |
CN1329022C (zh) | 2004-08-31 | 2007-08-01 | 贵州太和制药有限公司 | 亲水性生物粘附凝胶贴剂及其制备工艺 |
JP4799874B2 (ja) | 2005-01-25 | 2011-10-26 | 日東電工株式会社 | 貼付剤 |
JP2006288887A (ja) | 2005-04-13 | 2006-10-26 | Nitto Denko Corp | 貼付製剤 |
JP2007015963A (ja) | 2005-07-06 | 2007-01-25 | Hisamitsu Pharmaceut Co Inc | 貼付剤 |
MY149142A (en) | 2006-08-04 | 2013-07-15 | Hisamitsu Pharmaceutical Co | Adhesive preparation |
JP5075378B2 (ja) | 2006-09-08 | 2012-11-21 | 久光製薬株式会社 | 貼付剤製品 |
JP5201879B2 (ja) | 2007-05-30 | 2013-06-05 | 新東株式会社 | 瓦保持具 |
US20100178323A1 (en) | 2007-07-10 | 2010-07-15 | Agis Kydonieus | Dermal Delivery Device |
CA2713946C (en) | 2008-01-31 | 2015-12-15 | Tomomi Okada | Adhesive patch |
CN101530401A (zh) | 2008-03-12 | 2009-09-16 | 中山市中健药物研究所有限公司 | 一种用于治疗急慢性炎性疼痛的复方透皮贴片 |
EP2196197A1 (en) | 2008-12-15 | 2010-06-16 | Bouty S.P.A. | Antiviral patch |
EP2436380B1 (en) | 2009-05-29 | 2014-11-19 | Inoac Technical Center Co., Ltd. | Patch material |
TWI482645B (zh) | 2010-01-07 | 2015-05-01 | Teikoku Seiyaku Kk | 含有待克菲那(diclofenac)羥乙基吡咯啶之外用油性敷貼劑 |
JP5860201B2 (ja) | 2010-02-12 | 2016-02-16 | 久光製薬株式会社 | 経皮吸収製剤並びにその製造方法 |
WO2011136330A1 (ja) | 2010-04-30 | 2011-11-03 | ニチバン株式会社 | 貼付剤とその使用 |
CN102970989A (zh) | 2010-07-12 | 2013-03-13 | 永信药品工业股份有限公司 | 曲马多的双氯芬酸盐 |
WO2012022837A1 (en) | 2010-08-16 | 2012-02-23 | Helsingin Yliopisto | Transdermal compositions |
WO2013113690A1 (en) | 2012-01-31 | 2013-08-08 | Grünenthal GmbH | Pharmaceutical patch for transdermal administration of (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4-b]indol]-4-amine |
EP2859892B1 (en) | 2012-06-12 | 2023-06-07 | KM Transderm Ltd. | Patch |
EP2872177B1 (en) | 2012-07-12 | 2017-12-20 | Ferring BV | Diclofenac formulations |
JP5307931B1 (ja) | 2012-12-27 | 2013-10-02 | 久光製薬株式会社 | 貼付剤及びその製造方法 |
JP2014148582A (ja) | 2013-01-31 | 2014-08-21 | Sekisui Techno Seikei Kk | 樹脂組成物、これを用いてなる成形体及びその製造方法 |
JP2016508798A (ja) | 2013-02-26 | 2016-03-24 | パラパッチ,インク. | 女性失禁及び骨盤神経障害を治療するシステム及び方法 |
JP6270818B2 (ja) | 2013-03-21 | 2018-01-31 | ニチバン株式会社 | 無溶剤型のポリウレタン系粘着剤 |
JP2016135744A (ja) | 2013-05-08 | 2016-07-28 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
JP6268194B2 (ja) | 2014-01-10 | 2018-01-24 | 久光製薬株式会社 | 包装袋 |
US20170348246A1 (en) | 2014-12-26 | 2017-12-07 | Nichiban Co., Ltd. | Packaging body for patch and method of packing patch |
JP2016222631A (ja) | 2015-06-03 | 2016-12-28 | ポリプラスチックス株式会社 | 貼付剤用基材 |
EP3498272B1 (en) | 2016-10-11 | 2024-01-31 | Hisamitsu Pharmaceutical Co., Inc. | Oxybutynin-containing transdermal absorption preparation |
CN106619580A (zh) | 2016-11-28 | 2017-05-10 | 武汉理工大学 | 一种高分子材料制备的具有解热镇痛作用的外用贴剂 |
WO2018141661A1 (en) | 2017-01-31 | 2018-08-09 | Grünenthal GmbH | Pharmaceutical patch comprising lidocaine and diclofenac for treating neuropathic pain |
WO2018141662A1 (en) * | 2017-01-31 | 2018-08-09 | Grünenthal GmbH | Administration regimen for a pharmaceutical patch comprising lidocaine and diclofenac |
JP2019107220A (ja) | 2017-12-18 | 2019-07-04 | ニプロ株式会社 | 貼付剤用包装袋及び貼付剤製品 |
JP6761553B1 (ja) | 2020-02-12 | 2020-09-23 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
JP6744512B1 (ja) | 2020-02-12 | 2020-08-19 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
JP6744511B1 (ja) * | 2020-02-12 | 2020-08-19 | 久光製薬株式会社 | ジクロフェナクナトリウム含有貼付剤 |
-
2021
- 2021-02-25 US US17/184,797 patent/US11872320B2/en active Active
-
2022
- 2022-02-22 WO PCT/JP2022/007229 patent/WO2022181609A1/ja active Application Filing
- 2022-02-22 TW TW111106416A patent/TW202302079A/zh unknown
- 2022-02-22 JP JP2023502436A patent/JPWO2022181609A1/ja active Pending
- 2022-02-22 US US18/278,304 patent/US20240122870A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013191128A1 (ja) * | 2012-06-20 | 2013-12-27 | 久光製薬株式会社 | 貼付剤 |
WO2018124089A1 (ja) * | 2016-12-28 | 2018-07-05 | 久光製薬株式会社 | 貼付剤 |
Non-Patent Citations (4)
Title |
---|
AOKI, TORAKICHI ET AL.: "A Comparative Study of a Diclofenac Sodium Percutaneous Agent (TP318) and its Base Preparation in Treating Osteoarthrosis of the Knee Conclusion", JOURNAL OF CLINICAL THERAPEUTICS & MEDICINES, RINSHO IYAKU KENKYU KYOKAI, TOKYO,, JP, vol. 16, no. 4, 1 January 2000 (2000-01-01), JP , pages 427 - 443, XP009539246, ISSN: 0910-8211 * |
ITO, KUNIOMI ET AL.: "Clinical effect of diclofenac sodium tape preparation (Voltaren tape) on painful diseases", THERAPEUTIC RESEARCH, TOKYO, JP, vol. 26, no. 12, 1 January 2005 (2005-01-01), JP , pages 2333 - 2342, XP009539320, ISSN: 0289-8020 * |
MATSUNAGA, TAKANOBU ET AL.: "Usage experience on diclofenac-sodium cream for knee osteoarthritis and rheumatoid arthritis", JAPANESE PHARMACOLOGY AND THERAPEUTICS, RAIFU SAIENSU SHUPPAN, TOKYO., JP, vol. 11, no. 8, 1 January 1983 (1983-01-01), JP , pages 129 - 145, XP009539247, ISSN: 0386-3603 * |
RAKOOL PHARMACEUTICAL MARKETING CO., LTD.: "Diclofenac Na Pap 70mg "Rakul", 140mg "Rakul", 280mg "Rakul"", PMDA PACKAGE INSERT, PMDA, JP, 1 January 2016 (2016-01-01), JP, pages 1 - 2, XP009539402 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022181609A1 (ja) | 2022-09-01 |
US11872320B2 (en) | 2024-01-16 |
TW202302079A (zh) | 2023-01-16 |
US20220265567A1 (en) | 2022-08-25 |
US20240122870A1 (en) | 2024-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101032282B1 (ko) | 첩부제 | |
US9918945B2 (en) | Ropinirole-containing patch and package thereof | |
KR100971643B1 (ko) | 첩부제 | |
KR101902612B1 (ko) | 첩부제 | |
KR102477521B1 (ko) | 디클로페낙나트륨 함유 첩부제 | |
KR102477081B1 (ko) | 디클로페낙나트륨 함유 첩부제 | |
WO1998025592A1 (fr) | Preparation transdermique contenant un antagoniste des recepteurs de la serotonine | |
US20230071174A1 (en) | Diclofenac sodium-containing adhesive patch | |
JPH10152434A (ja) | 経皮吸収型製剤 | |
EP2143445B1 (en) | Medicated patch | |
WO2022181609A1 (ja) | 変形性関節症を治療するための貼付剤 | |
JP4283507B2 (ja) | 経皮投与用貼付剤 | |
EP2514424A1 (en) | Piroxicam-containing endermic preparation | |
TW202045157A (zh) | 羅替戈汀安定化方法 | |
JP2005529150A (ja) | 気管支拡張薬を有するマトリックスタイプパッチ | |
CN110869009B (zh) | 氨吡啶tts | |
TW201605498A (zh) | 含有可樂寧之貼劑 | |
JP2017001992A (ja) | 経皮吸収型製剤 | |
EP4360630A1 (en) | Method for inhibiting generation of diclofenac indolinones |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22759645 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023502436 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18278304 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22759645 Country of ref document: EP Kind code of ref document: A1 |